BCL2L11抗体;BCL2L11 Antibody—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-6: Rat kidney tissue, Raji, A549, Hela, A431, K562 cell lysates, Primary antibody: P12543(BCL2L11 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P12543(BCL2L11 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12543(BCL2L11 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The BCL2L11 gene encodes Bim (BCL-2 interacting mediator of cell death), a pro-apoptotic member of the BCL-2 protein family. Bim contains a BH3 domain critical for its function in promoting apoptosis by binding and neutralizing anti-apoptotic proteins like BCL-2 and BCL-xL. It is regulated transcriptionally and post-translationally, with activity influenced by growth factor signaling, stress stimuli, and phosphorylation. Bim exists as multiple isoforms (BimEL, BimL, BimS) generated by alternative splicing, each differing in apoptotic potency.

Antibodies targeting Bim are essential tools for studying its expression, localization, and interactions in apoptosis regulation. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and flow cytometry to assess Bim levels in diseases like cancer, where its downregulation is linked to therapy resistance. Specificity varies among antibodies; some detect all isoforms, while others target unique regions. Researchers also employ Bim antibodies to investigate its role in autoimmune disorders, neurodegenerative conditions, and hematopoietic cell homeostasis.

Therapeutic interest in Bim stems from its potential as a biomarker for treatment response and its involvement in mechanisms of BH3 mimetic drugs. Dysregulation of Bim contributes to pathological cell survival, making it a focus for developing strategies to restore apoptosis in resistant cancers.